Amgen at neutral by Merrill

Amgen Inc. was given a neutral rating by Merrill Lynch analyst Eric Ende on mixed results from the CERA hearing. While the case was not dismissed, it could be stayed after a hearing on Roche's motion to dismiss. The litigation could remain an overhang throughout 2006 and possibly into 2007. Shares of the Thousand Oaks, Calif., biotechnology company were down $0.26 or 0.38%, at $67.28 on volume of 7,578,898 shares versus the three-month running average of 10,187,600 shares. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.